Electromed (NYSE:ELMD) Downgraded by StockNews.com

StockNews.com cut shares of Electromed (NYSE:ELMD - Free Report) from a strong-buy rating to a buy rating in a report released on Thursday.

Separately, TheStreet raised shares of Electromed from a c+ rating to a b- rating in a research note on Wednesday, February 21st.

Electromed Stock Performance

Shares of ELMD stock traded down $0.19 on Thursday, reaching $13.94. The stock had a trading volume of 26,450 shares, compared to its average volume of 28,157. The stock has a market cap of $120.02 million, a P/E ratio of 31.51 and a beta of 0.43. Electromed has a 1 year low of $8.80 and a 1 year high of $17.85. The company has a 50 day simple moving average of $15.18 and a 200 day simple moving average of $12.09.

Electromed (NYSE:ELMD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $0.19 EPS for the quarter. Electromed had a return on equity of 10.32% and a net margin of 7.62%. The business had revenue of $13.69 million for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Gamco Investors INC. ET AL purchased a new position in shares of Electromed during the 4th quarter worth approximately $916,000. Royal Bank of Canada increased its stake in Electromed by 15.7% in the second quarter. Royal Bank of Canada now owns 150,125 shares of the company's stock valued at $1,608,000 after purchasing an additional 20,358 shares during the period. Riverwater Partners LLC increased its stake in Electromed by 83.5% in the third quarter. Riverwater Partners LLC now owns 32,684 shares of the company's stock valued at $340,000 after purchasing an additional 14,871 shares during the period. Cetera Advisor Networks LLC acquired a new position in Electromed in the second quarter valued at $129,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Electromed by 25.0% in the first quarter. Renaissance Technologies LLC now owns 53,504 shares of the company's stock valued at $556,000 after acquiring an additional 10,700 shares in the last quarter. Institutional investors and hedge funds own 40.82% of the company's stock.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function.